Alyeska Investment Group
SGYP

Alyeska Investment Group’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Alyeska Investment Group’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,355,681
Closed -$5.86M – 576
2017
Q3 		$6.83M Buy
2,355,681
+696,911
+42% +$2.38M 0.05% 271
2017
Q2 		$7.38M Sell
1,658,770
-50,265
-3% -$207K 0.06% 263
2017
Q1 		$7.96M Buy
+1,709,035
New +$9.91M 0.06% 268
2013
Q4 		– Sell
-101,400
Closed -$457K – 408
2013
Q3 		$457K Hold
101,400
– – 0.02% 287
2013
Q2 		$432K Buy
+101,400
New +$509K 0.02% 257

Other funds holding SGYP

TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Alyeska Investment Group's SGYP Position: Q4 2017 in Review

Alyeska Investment Group sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q4 2017, closing a stake of 2,355,681 shares — an estimated $5.86M sold.

Alyeska Investment Group first reported a position in SGYP in Q2 2013 and held it in 5 quarters. The position peaked at $7.96M in Q1 2017. 149 funds tracked by Wall St. Rank hold SGYP as of Q4 2017.

  • Alyeska Investment Group reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q4 2017 after selling out during the quarter.
  • Alyeska Investment Group sold 2,355,681 Synergy Pharmaceuticals, Inc Common Stock shares in Q4 2017, an estimated $5.86M.
  • Alyeska Investment Group first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and held it in 5 quarters.
  • Alyeska Investment Group's Synergy Pharmaceuticals, Inc Common Stock position peaked at $7.96M in Q1 2017.
  • 149 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q4 2017.

Based on Alyeska Investment Group's 13F filing for Q4 2017, filed 14 Feb 2018.